TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical countermeasures, hereby clarifies its update regarding the research study assessing Bucillamine as a potential treatment for nerve agent exposure. This study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centr ...

Psychedelic Medicine - Psychedelic medicine 行业关注 psilocybin（一种迷幻蘑菇中的活性成分）的潜力，这得益于最近的一项研究 [1] - Ibogaine（一种从非洲灌木 Iboga 中提取的物质）也被 Psychedelic medicine 行业关注，因为各州正在努力批准相关药物 [1]

Core Viewpoint - Psyence Group Inc. has successfully raised C$600,000 through a non-brokered private placement of common shares, with the first tranche completed and the second tranche expected to close soon [2][3]. Group 1: Offering Details - The Offering consists of two tranches, with Tranche 1 closing on June 25, 2025, raising C$476,000 by issuing 4,760,000 common shares at C$0.10 each [2]. - Tranche 2 is anticipated to close around July 4, 2025, for the remaining gross proceeds of C$124,000 [2]. - The net proceeds from the Offering will be allocated for general working capital purposes [2]. Group 2: Regulatory Compliance - The Offering was completed under the prospectus exemption available for accredited investors as per National Instrument 45-106 [3]. - All securities issued are subject to a statutory hold period of four months and one day from the issuance date, in accordance with Canadian securities laws [3]. - Resale restrictions may extend beyond the standard hold period if the company undertakes certain transactions or raises additional funds [3]. Group 3: Company Overview - Psyence Group Inc. is a life science biotechnology company focused on natural psychedelics, particularly psilocybin, for mental health and well-being [4][5]. - The company aims to develop nature-derived psilocybin products for clinical research and the treatment of psychological trauma [4][5].

Core Viewpoint - Red Light Holland Corp. has successfully partnered with Irvine Labs, which has received a Controlled Substances Import Permit for psilocybin raw materials, enabling the shipment of 3 kg of psilocybin truffles from the Netherlands to the United States for research and development purposes [2][3][6]. Company Overview - Red Light Holland is an Ontario-based corporation focused on the production, growth, and sale of functional mushrooms and psilocybin truffles in compliance with legal regulations in North America and Europe [2][10]. - Irvine Labs, established in 1997, specializes in medical research and development, particularly in natural medicines, and is licensed for drug manufacturing by the California Department of Public Health [4][9]. Regulatory Milestones - Irvine Labs has secured the Controlled Substances Import Permit, allowing the import of psilocybin raw materials, which is a significant regulatory achievement for the partnership [3][8]. - The import permit follows the 2025 psilocybin DEA quotas announced in April, indicating a structured regulatory framework for psilocybin research [2][6]. Research and Development Focus - The partnership aims to develop extended shelf-life microdosing capsules from psilocybin truffles, utilizing proprietary preservation technology to maintain product integrity [5][8]. - Both companies are committed to standardizing naturally occurring psilocybin and ensuring product stability and quality throughout the supply chain [5][8]. Market Potential - The collaboration aims to create a commercialized and standardized psilocybin product that can be legally exported to emerging markets and utilized in clinical trials and government-funded pilot programs in the United States [8][6].

Core Insights - Mind Medicine (MindMed) stock experienced an increase of over 8% following legislative developments in Connecticut regarding psilocybin decriminalization, contrasting with a 0.4% drop in the S&P 500 index [1] Legislative Developments - Connecticut's House of Representatives approved a bill to decriminalize psilocybin, with a narrow vote of 74 in favor and 65 against, which will now move to the state Senate for review [2] - If the bill passes, possession of up to half an ounce of psilocybin would incur only a $150 fine, eliminating jail time for violators [4] Therapeutic Benefits - Psilocybin has been recognized for its therapeutic potential in treating various mental health issues, including PTSD, addictions, depression, and anxiety disorders, as highlighted by state representative Steve Stafstrom [5] Public Sentiment and Industry Trends - There is a growing public support for the decriminalization of drugs and psychoactive substances, indicating a shift towards legalization that is already progressing in various jurisdictions across the U.S., which is favorable for companies like MindMed involved in psychedelic medicine [6]